WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006088833) INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088833    International Application No.:    PCT/US2006/005111
Publication Date: 24.08.2006 International Filing Date: 14.02.2006
IPC:
C07K 16/24 (2006.01), C07K 16/28 (2006.01), C07K 14/54 (2006.01), C07K 14/715 (2006.01), C12N 15/11 (2006.01), G01N 33/68 (2006.01), A61K 39/39 (2006.01), A61K 39/395 (2006.01), A61P 37/00 (2006.01), A61P 29/00 (2006.01), A61K 38/20 (2006.01)
Applicants: WYETH [US/US]; Five Giralda Farms, Madison, New Jersey 07940 (US) (For All Designated States Except US).
CARRENO, Beatriz, M. [US/US]; (US) (For US Only).
COLLINS, Mary [US/US]; (US) (For US Only).
WRIGHT, Jill, F. [US/US]; (US) (For US Only).
WOLFMAN, Neil, M. [US/US]; (US) (For US Only).
ARAI, Maya [US/US]; (US) (For US Only).
JACOBS, Kenneth [US/US]; (US) (For US Only).
LU, Zhijian [US/US]; (US) (For US Only).
GUO, Yongjing [CA/US]; (US) (For US Only).
QIU, Yongchang [CN/US]; (US) (For US Only)
Inventors: CARRENO, Beatriz, M.; (US).
COLLINS, Mary; (US).
WRIGHT, Jill, F.; (US).
WOLFMAN, Neil, M.; (US).
ARAI, Maya; (US).
JACOBS, Kenneth; (US).
LU, Zhijian; (US).
GUO, Yongjing; (US).
QIU, Yongchang; (US)
Agent: PIERONI, Joseph, P.; Fitzpatrick, Cella, Harper & Scinto, 30 Rockefeller Plaza, New York, New York 10112-3801 (US)
Priority Data:
60/653,260 14.02.2005 US
60/667,492 01.04.2005 US
Title (EN) INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
(FR) ANTICORPS DE L'INTERLEUKINE-17F ET D'AUTRES ANTAGONISTES DE SIGNALISATION DE L'IL-17F ET LEURS UTILISATIONS CORRESPONDANTES
Abstract: front page image
(EN)The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.
(FR)La présente invention a trait à des polynucléotides isolés et purifiés et à des polypeptides associés à la voie de signalisation de l'IL-17F. L'invention a également trait à des anticorps aux homodimères de l'IL-17F et aux hétérodimères de l'IL-17F, à des procédés pour l'isolement et la purification de membres de la famille de l'IL-17F, comprenant des hétérodimères de l'IL-17A/IL-17F, provenant d'une source naturelle. La présente invention a trait en outre à de nouveaux procédés pour le diagnostic, le pronostic, le suivi du développement, et le traitement ou la prévention de troubles associés à la signalisation de l'IL-17F, c'est à dire des troubles associés à l'IL-17F, comprenant, mais de manière non limitative, des troubles inflammatoires, tels que des maladies auto-immunes, (par exemple, l'arthrite (y compris la polyarthrite rhumatoïde), le psoriasis, le lupus érythémateux systémique, et la sclérose en plaques)), des maladies respiratoires (par exemple, la broncho-pneumopathie chronique obstructive, la fibrose cystique, l'asthme, l'allergie), le rejet de greffe (y compris le rejet de greffe d'organes solides), et des maladies et troubles intestinaux inflammatoires (par exemple, la colite ulcéreuse, la maladie de Crohn). La présente invention a enfin trait à de nouveaux agents thérapeutiques et de nouvelles cibles thérapeutiques, et à des procédés de criblage et d'évaluation de composés d'essai pour l'intervention (le traitement) et la prévention de troubles liés à la signalisation de l'IL-17F.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)